Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
Status:
NOT_YET_RECRUITING
Trial end date:
2027-11-30
Target enrollment:
Participant gender:
Summary
The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of placebo and semaglutide therapy in 74 KTR at risk of post-transplant diabetes mellitus (PTDM).